Sodium glucose cotransporter 2 (SGLT2) inhibitors are the first treatment proven to slow progression of kidney disease in people with CKD in almost two decades. This webinar is proudly sponsored by AstraZeneca.
Thursday, 2 September 2021
7.30pm - 8.30pm AEST
Click here to check your local time
Sodium glucose cotransporter 2 (SGLT2) inhibitors are the first treatment proven to slow progression of kidney disease in people with CKD in almost two decades.
This webinar summarises key evidence from landmark clinical trials that have established this treatment as standard of care for people with diabetic nephropathy in major international clinical practice guidelines, discusses practical considerations related to their use in routine clinical practice, and explores how these agents may be use in even more broad populations in the next 3-5 years.
|
|
Dr Brendon Neuen is a nephrology advanced trainee and NHMRC Postgraduate Scholar at The George Institute for Global Health, UNSW Sydney. He graduated in medicine at James Cook University with 1st Class Honours and an Academic Medal and holds a Masters in Global Health from the University of Oxford, where he was fully funded by a Clarendon Scholarship and received the prize for the top ranked dissertation. He is an internationally recognised expert on the efficacy and safety of SGLT2 inhibitors in people with diabetes and chronic kidney disease, having led several analyses of the CANVAS and CREDENCE trials, and is regularly invited to speak at national and international meetings on this topic. He is involved in several ongoing international multi-centre randomized trials and has published over 80 peer-reviewed articles and conference proceedings in general medical journals including The Lancet, BMJ and Annals of Internal Medicine, and specialty journals including Lancet Diabetes and Endocrinology, Circulation, and the Journal of the American Society of Nephrology. His work has directly informed major international clinical practice guidelines which define best practice for the care of people with type 2 diabetes and kidney disease, including the Kidney Disease Improving Global Outcomes (KDIGO) Guidelines and the American Diabetes Association (ADA) Standards of Care. In addition, he serves on committees of the Australasian Kidney Trials Network and the International Society of Nephrology. |
Dr Leanne Brown, RSA Vice-President
Your computer or mobile device
Details will be provided to registrants via email prior to the live broadcast. PS -- Make sure to check your junk or spam inbox.
RSA Members - FREE of Charge
Non-Members - AU$15.00 inc GST
Not a RSA member? Join now!
1 hour
